Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: A meta-analysis of five randomized controlled trials

Colorectal Disease

Volumn 13, Issue 8, 2011, Pages 837-845

  Bin, Q ^a   Li, J ^a   Liao, C ^a   Cao, Y ^a   Gao, F ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

5 fluoro uracil; Colorectal cancer; Meta analysis; Uracil tegafur

Indexed keywords

FLUOROURACIL; FOLINIC ACID; UFT;

ADVANCED CANCER; ARTICLE; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COCHRANE LIBRARY; COLORECTAL CANCER; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EMBASE; FEBRILE NEUTROPENIA; HAZARD RATIO; HUMAN; INFECTION; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; MEDLINE; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMATITIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DIARRHEA; FLUOROURACIL; HUMANS; INFECTION; LEUCOVORIN; LEUKOPENIA; MUCOSITIS; NEUTROPENIA; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMATITIS; SURVIVAL ANALYSIS; TEGAFUR; URACIL;

EID: 79960445374     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2009.02184.x     Document Type: Article

References (41)

1. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985: implications for prevention and projections of future burden. Int J Cancer 1993; 55: 891-903.
2. Thirion P, Michiels S, Pignon JP et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22: 3766-75.
3. Van Triest B, van Groeningen CJ, Pinedo HM. Current chemotherapeutic possibilities in the treatment of colorectal cancer. Eur J Cancer 1995; 31A: 1193-7.
4. Beretta G, Bollina R, Cozzi C et al. Should we consider the weekly chemotherapy with fluorouracil - racemic folinic acid a standard treatment for advanced/metastatic carcinoma of digestive tract in elderly patients? Proc Am Soc Clin Oncol 1997; 16: 259a.
5. Scheithauer W, Rosen H, Kornek G-V, Sebesta C, Depisch D Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306: 752-5.
6. Glimelius B, Hoffman K, Graf W et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995; 6: 267-74.
7. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992; 10: 896-903.
8. Poon MA, O'Connell MJ, Moertel CM. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407-18.
9. Babbio-Pallavicini E, Porta C, Moroni M, Spaghi A, Casagranda I, Nastasi G. Folinic acid does improve 5-fluorouracil activity in vivo: results of a phase III study comparing 5-fluorouracil to 5-fluorouracil and folinic acid in advanced colon cancer patients. J Chemother 1993; 5: 52-5.
10. Borner MM, Castiglione M, Bacchi M et al. The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1998; 9: 535-41.
11. Petrioli R, Lorenzi M, Aquino A et al. Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care. Eur J Cancer 1995; 31A: 2105-8.
12. Erlichman C, Fine S, Wong A, Elhakim T. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988; 6: 469-72.
13. Wolmark N, Rockette H, Mamounas E et al. Clinical trial to assess the relative efficacy of fluorouracil and levamisole, fluorouracil and leucovorin and fluorouracil, leucovorin and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C04. J Clin Oncol 1999; 17: 3553-9.
14. Maehara Y, Kakeji Y, Ohno S, Baba H, Sugimachi K. Scientific basis for the combination of tegafur with uracil. Oncology (Williston Park) 1997; 11: 14-21.
15. Rustum YM. Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation. Oncology 1997; 54(Suppl. 1): 7-11.
16. Okabe H, Toko T, Saito H et al. Augmentation of the chemotherapeutic effectiveness of UFT, a combination of tegafur [1-(2- tetrahydrofuryl)-5-fluorouracil] with uracil, by oral l-leucovorin. Anticancer Res 1997; 17: 157-64.
17. Cao S, Frank C, Shirasaka T, Rustum YM. 5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer. Clin Cancer Res 1995; 1: 839-45.
18. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008.
19. Sutton AJ, Abrams KR, Jones DR et al. (2000) Methods for Meta-analysis in Medical Research. Wiley, Chichester.
20. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-101.
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
22. Carmichael J. UFT plus leucovorin vs 5-FU plus leucovorin for metastatic colorectal cancer. Oncology (Williston Park) 1997; 11(9 Suppl. 10): 50-2.
23. Skillings JR. 5-FU or UFT combined with leucovorin for previously untreated metastatic colorectal cancer. Oncology (Williston Park) 1997; 11(9 Suppl. 10): 48-9.
24. Smith RE, Lembersky BC, Wieand HS, Colangelo L, Mamounas EP. UFT/leucovorin vs 5-FU/leucovorin in colon cancer. Oncology (Williston Park) 2000; 14(10 Suppl. 9): 24-7.
25. Lembersky BC, Wieand HS, Petrelli NJ et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006; 24: 2059-64.
26. Carmichael J, Popiela T, Radstone D et al. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20: 3617-27.
27. Douillard JY, Hoff PM, Skillings JR et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20: 3605-16.
28. Lima AP, del Giglio A. Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience. Eur J Cancer Care (Engl) 2005; 14: 151-4.
29. de la Torre A, García-Berrocal MI, Arias F et al. Preoperative chemoradiotherapy for rectal cancer: randomized trial comparing oral uracil and tegafur and oral leucovorin vs. intravenous 5-fluorouracil and leucovorin. Int J Radiat Oncol Biol Phys 2008; 70: 102-10.
30. O'Connell MJ, Mailliard JA, Kahn MJ et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15: 246-50.
31. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer: International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345: 939-44.
32. Sakamoto J, Ohashi Y, Hamada C et al. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 2004; 22: 484-92.
33. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 2002; 7: 288-323.
34. Kuhn JG. Fluorouracil and the new oral fluorinated pyrimidines. Ann Pharmacother 2001; 35: 217-27.
35. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988; 22: 333-8.
36. Yonekura K, Basaki Y, Chikahisa L et al. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res 1999; 5: 2185-91.
37. Sugimachi K, Maehara Y, Ogawa M, Kakegawa T, Tomita M. Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer. Cancer Chemother Pharmacol 1997; 40: 233-8.
38. Danno M, Shiroto H, Kunii Y et al. Study on the intensity of MMC and UFT in postoperative adjuvant chemotherapy for gastric cancer-study report of JFMTC Study No. 10. Jpn J Cancer Chemother 2001; 28: 195-203.
39. Feliu J, González Barón M, Espinosa E. Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Cancer 1997; 79: 1884-9.
40. Douillard J, Seitz J. A phase I study of oral uracil/tegafur (UFT) plus leucovorin (LV) combined with oxaliplatin in patients with metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 2001; 20: 144a.
41. Hill M, Mackay H, Cunningham D et al. Phase I/II study of oral uracil/tegafur (UFT) leucovorin and irinotecan in patients with advanced colorectal cancer. Ann Oncol 2000; 11(Suppl. 4, Abstract 193P): 45.